Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Journal of Hematology & Oncology
Published in: Journal of Hematology & Oncology 1/2023

Open Access 01-12-2023 | Review

Involvement of inflammasomes in tumor microenvironment and tumor therapies

Authors: Ziqi Zhang, Xue Li, Yang Wang, Yuquan Wei, Xiawei Wei

Published in: Journal of Hematology & Oncology | Issue 1/2023

Login to get access

Abstract

Inflammasomes are macromolecular platforms formed in response to damage-associated molecular patterns (DAMPs) and pathogen-associated molecular patterns, whose formation would cause maturation of interleukin-1 (IL-1) family members and gasdermin D (GSDMD), leading to IL-1 secretion and pyroptosis respectively. Several kinds of inflammasomes detecting different types of dangers have been found. The activation of inflammasomes is regulated at both transcription and posttranscription levels, which is crucial in protecting the host from infections and sterile insults. Present findings have illustrated that inflammasomes are involved in not only infection but also the pathology of tumors implying an important link between inflammation and tumor development. Generally, inflammasomes participate in tumorigenesis, cell death, metastasis, immune evasion, chemotherapy, target therapy, and radiotherapy. Inflammasome components are upregulated in some tumors, and inflammasomes can be activated in cancer cells and other stromal cells by DAMPs, chemotherapy agents, and radiation. In some cases, inflammasomes inhibit tumor progression by initiating GSDMD-mediated pyroptosis in cancer cells and stimulating IL-1 signal-mediated anti-tumor immunity. However, IL-1 signal recruits immunosuppressive cell subsets in other cases. We discuss the conflicting results and propose some possible explanations. Additionally, we also summarize interventions targeting inflammasome pathways in both preclinical and clinical stages. Interventions targeting inflammasomes are promising for immunotherapy and combination therapy.
Literature
1.
2.
Balka KR, De Nardo D. Understanding early TLR signaling through the myddosome. J Leukoc Biol. 2019;105(2):339–51.PubMedCrossRef
3.
4.
5.
Broz P, Dixit VM. Inflammasomes: mechanism of assembly, regulation and signalling. Nat Rev Immunol. 2016;16(7):407–20.PubMedCrossRef
6.
Cai X, Chen J, Xu H, et al. Prion-like polymerization underlies signal transduction in antiviral immune defense and inflammasome activation. Cell. 2014;156(6):1207–22.PubMedPubMedCentralCrossRef
7.
8.
9.
Faustin B, Lartigue L, Bruey JM, et al. Reconstituted NALP1 inflammasome reveals two-step mechanism of caspase-1 activation. Mol Cell. 2007;25(5):713–24.PubMedCrossRef
10.
Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-β. Mol Cell. 2002;10(2):417–26.PubMedCrossRef
11.
Proell M, Gerlic M, Mace PD, et al. The CARD plays a critical role in ASC foci formation and inflammasome signalling. Biochem J. 2013;449(3):613–21.PubMedCrossRef
12.
Poyet JL, Srinivasula SM, Tnani M, et al. Identification of Ipaf, a human caspase-1-activating protein related to Apaf-1. J Biol Chem. 2001;276(30):28309–13.PubMedCrossRef
13.
Boucher D, Monteleone M, Coll RC, et al. Caspase-1 self-cleavage is an intrinsic mechanism to terminate inflammasome activity. J Exp Med. 2018;215(3):827–40.PubMedPubMedCentralCrossRef
14.
Afonina IS, Muller C, Martin SJ, et al. Proteolytic processing of interleukin-1 family cytokines: variations on a common theme. Immunity. 2015;42(6):991–1004.PubMedCrossRef
15.
16.
Ding J, Wang K, Liu W, et al. Pore-forming activity and structural autoinhibition of the gasdermin family. Nature. 2016;535(7610):111–6.PubMedCrossRef
17.
18.
Evavold CL, Hafner-Bratkovic I, Devant P, et al. Control of gasdermin D oligomerization and pyroptosis by the ragulator-rag-mTORC1 pathway. Cell. 2021;184(17):4495–511.PubMedPubMedCentralCrossRef
19.
Weindel CG, Martinez EL, Zhao X, et al. Mitochondrial ROS promotes susceptibility to infection via gasdermin D-mediated necroptosis. Cell. 2022;185(17):3214–31.PubMedCrossRef
20.
Rogers C, Erkes DA, Nardone A, et al. Gasdermin pores permeabilize mitochondria to augment caspase-3 activation during apoptosis and inflammasome activation. Nat Commun. 2019;10(1):1689.PubMedPubMedCentralCrossRef
21.
Chan AH, Schroder K. Inflammasome signaling and regulation of interleukin-1 family cytokines. J Exp Med. 2020;217(1):e20190314.PubMedCrossRef
22.
23.
24.
25.
Shi J, Zhao Y, Wang Y, et al. Inflammatory caspases are innate immune receptors for intracellular LPS. Nature. 2014;514(7521):187–92.PubMedCrossRef
26.
Vigano E, Diamond CE, Spreafico R, et al. Human caspase-4 and caspase-5 regulate the one-step non-canonical inflammasome activation in monocytes. Nat Commun. 2015;6:8761.PubMedCrossRef
27.
Ross C, Chan AH, Von Pein J, et al. Dimerization and auto-processing induce caspase-11 protease activation within the non-canonical inflammasome. Life Sci Alliance. 2018;1(6): e201800237.PubMedPubMedCentralCrossRef
28.
Yang J, Zhao Y, Shao F. Non-canonical activation of inflammatory caspases by cytosolic LPS in innate immunity. Curr Opin Immunol. 2015;32:78–83.PubMedCrossRef
29.
Kayagaki N, Stowe IB, Lee BL, et al. Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling. Nature. 2015;526(7575):666–71.PubMedCrossRef
30.
Shi J, Zhao Y, Wang K, et al. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature. 2015;526(7575):660–5.PubMedCrossRef
31.
Ruhl S, Broz P. Caspase-11 activates a canonical NLRP3 inflammasome by promoting K(+) efflux. Eur J Immunol. 2015;45(10):2927–36.PubMedCrossRef
32.
Kobayashi T, Ogawa M, Sanada T, et al. The Shigella OspC3 effector inhibits caspase-4, antagonizes inflammatory cell death, and promotes epithelial infection. Cell Host Microbe. 2013;13(5):570–83.PubMedCrossRef
33.
Knodler LA, Crowley SM, Sham HP, et al. Noncanonical inflammasome activation of caspase-4/caspase-11 mediates epithelial defenses against enteric bacterial pathogens. Cell Host Microbe. 2014;16(2):249–56.PubMedPubMedCentralCrossRef
34.
Wiggins KA, Parry AJ, Cassidy LD, et al. IL-1alpha cleavage by inflammatory caspases of the noncanonical inflammasome controls the senescence-associated secretory phenotype. Aging Cell. 2019;18(3): e12946.PubMedPubMedCentralCrossRef
35.
Mandal R, Barron JC, Kostova I, et al. Caspase-8: the double-edged sword. Biochim Biophys Acta Rev Cancer. 2020;1873(2): 188357.PubMedCrossRef
36.
Bossaller L, Chiang PI, Schmidt-Lauber C, et al. Cutting edge: FAS (CD95) mediates noncanonical IL-1beta and IL-18 maturation via caspase-8 in an RIP3-independent manner. J Immunol. 2012;189(12):5508–12.PubMedCrossRef
37.
Gringhuis SI, Kaptein TM, Wevers BA, et al. Dectin-1 is an extracellular pathogen sensor for the induction and processing of IL-1beta via a noncanonical caspase-8 inflammasome. Nat Immunol. 2012;13(3):246–54.PubMedCrossRef
38.
Ketelut-Carneiro N, Ghosh S, Levitz SM, et al. A dectin-1-caspase-8 pathway licenses canonical caspase-1 inflammasome activation and interleukin-1beta release in response to a pathogenic fungus. J Infect Dis. 2018;217(2):329–39.PubMedCrossRef
39.
Vajjhala PR, Lu A, Brown DL, et al. The Inflammasome adaptor ASC induces procaspase-8 death effector domain filaments. J Biol Chem. 2015;290(49):29217–30.PubMedPubMedCentralCrossRef
40.
Antonopoulos C, Russo HM, El Sanadi C, et al. Caspase-8 as an effector and regulator of NLRP3 inflammasome signaling. J Biol Chem. 2015;290(33):20167–84.PubMedPubMedCentralCrossRef
41.
Man SM, Tourlomousis P, Hopkins L, et al. Salmonella infection induces recruitment of caspase-8 to the inflammasome to modulate IL-1beta production. J Immunol. 2013;191(10):5239–46.PubMedCrossRef
42.
Rühl S, Shkarina K, Demarco B, et al. ESCRT-dependent membrane repair negatively regulates pyroptosis downstream of GSDMD activation. 2018.
43.
Aglietti RA, Estevez A, Gupta A, et al. GsdmD p30 elicited by caspase-11 during pyroptosis forms pores in membranes. Proc Natl Acad Sci U S A. 2016;113(28):7858–63.PubMedPubMedCentralCrossRef
44.
Magupalli VG, Negro R, Tian Y, et al. HDAC6 mediates an aggresome-like mechanism for NLRP3 and pyrin inflammasome activation. Science. 2020;369(6510):eaas8995.PubMedPubMedCentralCrossRef
45.
Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell. 2002;10(2):417–26.PubMedCrossRef
46.
47.
Masters SL, Gerlic M, Metcalf D, et al. NLRP1 inflammasome activation induces pyroptosis of hematopoietic progenitor cells. Immunity. 2012;37(6):1009–23.PubMedPubMedCentralCrossRef
48.
Boyden ED, Dietrich WF. Nalp1b controls mouse macrophage susceptibility to anthrax lethal toxin. Nat Genet. 2006;38(2):240–4.PubMedCrossRef
49.
Okondo MC, Johnson DC, Sridharan R, et al. DPP8 and DPP9 inhibition induces pro-caspase-1-dependent monocyte and macrophage pyroptosis. Nat Chem Biol. 2017;13(1):46–53.PubMedCrossRef
50.
Bauernfried S, Scherr MJ, Pichlmair A, et al. Human NLRP1 is a sensor for double-stranded RNA. Science. 2021;371(6528):eabd0811.PubMedCrossRef
51.
Robinson KS, Toh GA, Rozario P, et al. ZAKα-driven ribotoxic stress response activates the human NLRP1 inflammasome. Science. 2022;377(6603):328–35.PubMedPubMedCentralCrossRef
52.
Hollingsworth LR, Sharif H, Griswold AR, et al. DPP9 sequesters the C terminus of NLRP1 to repress inflammasome activation. Nature. 2021;592(7856):778–83.PubMedPubMedCentralCrossRef
53.
54.
Sandstrom A, Mitchell PS, Goers L, et al. Functional degradation: a mechanism of NLRP1 inflammasome activation by diverse pathogen enzymes. Science. 2019;364(6435):eaau1330.PubMedPubMedCentralCrossRef
55.
56.
Van Opdenbosch N, Gurung P, Vande Walle L, et al. Activation of the NLRP1b inflammasome independently of ASC-mediated caspase-1 autoproteolysis and speck formation. Nat Commun. 2014;5:3209.PubMedCrossRef
57.
Witola WH, Mui E, Hargrave A, et al. NALP1 influences susceptibility to human congenital toxoplasmosis, proinflammatory cytokine response, and fate of toxoplasma gondii-infected monocytic cells. Infect Immun. 2011;79(2):756–66.PubMedCrossRef
58.
Drutman SB, Haerynck F, Zhong FL, et al. Homozygous NLRP1 gain-of-function mutation in siblings with a syndromic form of recurrent respiratory papillomatosis. Proc Natl Acad Sci U S A. 2019;116(38):19055–63.PubMedPubMedCentralCrossRef
59.
Zhong FL, Mamai O, Sborgi L, et al. Germline NLRP1 mutations cause skin inflammatory and cancer susceptibility syndromes via inflammasome activation. Cell. 2016;167(1):187–202.PubMedCrossRef
60.
Magitta NF, Boe Wolff AS, Johansson S, et al. A coding polymorphism in NALP1 confers risk for autoimmune Addison’s disease and type 1 diabetes. Genes Immun. 2009;10(2):120–4.PubMedCrossRef
61.
Duncan JA, Bergstralh DT, Wang Y, et al. Cryopyrin/NALP3 binds ATP/dATP, is an ATPase, and requires ATP binding to mediate inflammatory signaling. Proc Natl Acad Sci U S A. 2007;104(19):8041–6.PubMedPubMedCentralCrossRef
62.
Andreeva L, David L, Rawson S, et al. NLRP3 cages revealed by full-length mouse NLRP3 structure control pathway activation. Cell. 2021;184(26):6299–312.PubMedPubMedCentralCrossRef
63.
Hochheiser IV, Pilsl M, Hagelueken G, et al. Structure of the NLRP3 decamer bound to the cytokine release inhibitor CRID3. Nature. 2022;604(7904):184–9.PubMedCrossRef
64.
Bauernfeind FG, Horvath G, Stutz A, et al. Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J Immunol. 2009;183(2):787–91.PubMedCrossRef
65.
Franchi L, Eigenbrod T, Nunez G. Cutting edge: TNF-alpha mediates sensitization to ATP and silica via the NLRP3 inflammasome in the absence of microbial stimulation. J Immunol. 2009;183(2):792–6.PubMedCrossRef
66.
Marucha PT, Zeff RA, Kreutzer DL. Cytokine regulation of IL-1 beta gene expression in the human polymorphonuclear leukocyte. J Immunol. 1990;145(9):2932–7.PubMedCrossRef
67.
Song N, Liu ZS, Xue W, et al. NLRP3 phosphorylation is an essential priming event for inflammasome activation. Mol Cell. 2017;68(1):185–97.PubMedCrossRef
68.
Juliana C, Fernandes-Alnemri T, Kang S, et al. Non-transcriptional priming and deubiquitination regulate NLRP3 inflammasome activation. J Biol Chem. 2012;287(43):36617–22.PubMedPubMedCentralCrossRef
69.
Py BF, Kim MS, Vakifahmetoglu-Norberg H, et al. Deubiquitination of NLRP3 by BRCC3 critically regulates inflammasome activity. Mol Cell. 2013;49(2):331–8.PubMedCrossRef
70.
Lamkanfi M, Dixit VM. Inflammasomes and their roles in health and disease. Annu Rev Cell Dev Biol. 2012;28:137–61.PubMedCrossRef
71.
Ng J, Hirota SA, Gross O, et al. Clostridium difficile toxin-induced inflammation and intestinal injury are mediated by the inflammasome. Gastroenterology. 2010;139(2):542–52.PubMedCrossRef
72.
Lee MS, Kwon H, Lee EY, et al. Shiga toxins activate the NLRP3 inflammasome pathway to promote both production of the proinflammatory cytokine interleukin-1beta and apoptotic cell death. Infect Immun. 2016;84(1):172–86.PubMedCrossRef
73.
Munoz-Planillo R, Kuffa P, Martinez-Colon G, et al. K(+) efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter. Immunity. 2013;38(6):1142–53.PubMedPubMedCentralCrossRef
74.
Platnich JM, Chung H, Lau A, et al. Shiga toxin/lipopolysaccharide activates caspase-4 and gasdermin D to trigger mitochondrial reactive oxygen species upstream of the NLRP3 inflammasome. Cell Rep. 2018;25(6):1525–36.PubMedCrossRef
75.
Hornung V, Bauernfeind F, Halle A, et al. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol. 2008;9(8):847–56.PubMedPubMedCentralCrossRef
76.
Murakami T, Ockinger J, Yu J, et al. Critical role for calcium mobilization in activation of the NLRP3 inflammasome. Proc Natl Acad Sci U S A. 2012;109(28):11282–7.PubMedPubMedCentralCrossRef
77.
78.
Subramanian N, Natarajan K, Clatworthy MR, et al. The adaptor MAVS promotes NLRP3 mitochondrial localization and inflammasome activation. Cell. 2013;153(2):348–61.PubMedPubMedCentralCrossRef
79.
Zhao K, Zhang Y, Xu X, et al. Acetylation is required for NLRP3 self-aggregation and full activation of the inflammasome. 2019.
80.
Xiao L, Magupalli VG, Wu H. Cryo-EM structures of the active NLRP3 inflammasome disc. Nature. 2023;613(7944):595–600.PubMedCrossRef
81.
Van Gorp H, Van Opdenbosch N, Lamkanfi M. Inflammasome-dependent cytokines at the crossroads of health and autoinflammatory disease. Cold Spring Harb Perspect Biol. 2019;11(1):a028563.PubMedPubMedCentralCrossRef
82.
Hoffman HM, Mueller JL, Broide DH, et al. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet. 2001;29(3):301–5.PubMedPubMedCentralCrossRef
83.
Brydges SD, Broderick L, McGeough MD, et al. Divergence of IL-1, IL-18, and cell death in NLRP3 inflammasomopathies. J Clin Invest. 2013;123(11):4695–705.PubMedPubMedCentralCrossRef
84.
Lee GS, Subramanian N, Kim AI, et al. The calcium-sensing receptor regulates the NLRP3 inflammasome through Ca2+ and cAMP. Nature. 2012;492(7427):123–7.PubMedPubMedCentralCrossRef
85.
Bauer R, Rauch I. The NAIP/NLRC4 inflammasome in infection and pathology. Mol Aspects Med. 2020;76: 100863.PubMedCrossRef
86.
Broz P, von Moltke J, Jones JW, et al. Differential requirement for caspase-1 autoproteolysis in pathogen-induced cell death and cytokine processing. Cell Host Microbe. 2010;8(6):471–83.PubMedPubMedCentralCrossRef
87.
Mariathasan S, Newton K, Monack DM, et al. Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf. Nature. 2004;430(6996):213–8.PubMedCrossRef
88.
Mascarenhas DPA, Cerqueira DM, Pereira MSF, et al. Inhibition of caspase-1 or gasdermin-D enable caspase-8 activation in the Naip5/NLRC4/ASC inflammasome. PLoS Pathog. 2017;13(8): e1006502.PubMedPubMedCentralCrossRef
89.
Amer A, Franchi L, Kanneganti TD, et al. Regulation of Legionella phagosome maturation and infection through flagellin and host Ipaf. J Biol Chem. 2006;281(46):35217–23.PubMedCrossRef
90.
Miao EA, Mao DP, Yudkovsky N, et al. Innate immune detection of the type III secretion apparatus through the NLRC4 inflammasome. Proc Natl Acad Sci U S A. 2010;107(7):3076–80.PubMedPubMedCentralCrossRef
91.
92.
Zhao Y, Yang J, Shi J, et al. The NLRC4 inflammasome receptors for bacterial flagellin and type III secretion apparatus. Nature. 2011;477(7366):596–600.PubMedCrossRef
93.
Yang J, Zhao Y, Shi J, et al. Human NAIP and mouse NAIP1 recognize bacterial type III secretion needle protein for inflammasome activation. Proc Natl Acad Sci U S A. 2013;110(35):14408–13.PubMedPubMedCentralCrossRef
94.
Kortmann J, Brubaker SW, Monack DM. Cutting edge: inflammasome activation in primary human macrophages is dependent on flagellin. J Immunol. 2015;195(3):815–9.PubMedPubMedCentralCrossRef
95.
Romberg N, Al Moussawi K, Nelson-Williams C, et al. Mutation of NLRC4 causes a syndrome of enterocolitis and autoinflammation. Nat Genet. 2014;46(10):1135–9.PubMedPubMedCentralCrossRef
96.
Canna SW, de Jesus AA, Gouni S, et al. An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome. Nat Genet. 2014;46(10):1140–6.PubMedPubMedCentralCrossRef
97.
98.
Bae JH, Jo SI, Kim SJ, et al. Circulating cell-free mtDNA contributes to AIM2 inflammasome-mediated chronic inflammation in patients with type 2 diabetes. Cells. 2019;8(4):328.PubMedPubMedCentralCrossRef
99.
100.
Rathinam VA, Jiang Z, Waggoner SN, et al. The AIM2 inflammasome is essential for host defense against cytosolic bacteria and DNA viruses. Nat Immunol. 2010;11(5):395–402.PubMedPubMedCentralCrossRef
101.
Smith S, Jefferies C. Role of DNA/RNA sensors and contribution to autoimmunity. Cytokine Growth Factor Rev. 2014;25(6):745–57.PubMedCrossRef
102.
103.
Woerner SM, Kloor M, Schwitalle Y, et al. The putative tumor suppressor AIM2 is frequently affected by different genetic alterations in microsatellite unstable colon cancers. Genes Chromosom Cancer. 2007;46(12):1080–9.PubMedCrossRef
104.
105.
Dihlmann S, Tao S, Echterdiek F, et al. Lack of absent in melanoma 2 (AIM2) expression in tumor cells is closely associated with poor survival in colorectal cancer patients. Int J Cancer. 2014;135(10):2387–96.PubMedCrossRef
106.
107.
Park YH, Wood G, Kastner DL, et al. Pyrin inflammasome activation and RhoA signaling in the autoinflammatory diseases FMF and HIDS. Nat Immunol. 2016;17(8):914–21.PubMedPubMedCentralCrossRef
108.
Gao W, Yang J, Liu W, et al. Site-specific phosphorylation and microtubule dynamics control Pyrin inflammasome activation. Proc Natl Acad Sci. 2016;113(33):E4857–66.PubMedPubMedCentralCrossRef
109.
110.
111.
Rider P, Carmi Y, Guttman O, et al. IL-1alpha and IL-1beta recruit different myeloid cells and promote different stages of sterile inflammation. J Immunol. 2011;187(9):4835–43.PubMedCrossRef
112.
Werman A, Werman-Venkert R, White R, et al. The precursor form of IL-1alpha is an intracrine proinflammatory activator of transcription. Proc Natl Acad Sci U S A. 2004;101(8):2434–9.PubMedPubMedCentralCrossRef
113.
114.
Schroder K, Hertzog PJ, Ravasi T, et al. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol. 2004;75(2):163–89.PubMedCrossRef
115.
116.
Cao X, Xu J. Insights into inflammasome and its research advances in cancer. Tumori. 2019;105(6):456–64.PubMedCrossRef
117.
Ershaid N, Sharon Y, Doron H, et al. NLRP3 inflammasome in fibroblasts links tissue damage with inflammation in breast cancer progression and metastasis. Nat Commun. 2019;10(1):4375.PubMedPubMedCentralCrossRef
118.
Weichand B, Popp R, Dziumbla S, et al. S1PR1 on tumor-associated macrophages promotes lymphangiogenesis and metastasis via NLRP3/IL-1beta. J Exp Med. 2017;214(9):2695–713.PubMedPubMedCentralCrossRef
119.
Das S, Shapiro B, Vucic EA, et al. Tumor cell-derived IL1beta promotes desmoplasia and immune suppression in pancreatic cancer. Cancer Res. 2020;80(5):1088–101.PubMedPubMedCentralCrossRef
120.
Bruchard M, Mignot G, Derangere V, et al. Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat Med. 2013;19(1):57–64.PubMedCrossRef
121.
Tu CE, Hu Y, Zhou P, et al. Lactate and TGF-beta antagonistically regulate inflammasome activation in the tumor microenvironment. J Cell Physiol. 2021;236(6):4528–37.PubMedCrossRef
122.
Ju M, Bi J, Wei Q, et al. Pan-cancer analysis of NLRP3 inflammasome with potential implications in prognosis and immunotherapy in human cancer. Brief Bioinform. 2020.
123.
Zheng T, Wang X, Yue P, et al. Prognostic inflammasome-related signature construction in kidney renal clear cell carcinoma based on a pan-cancer landscape. Evid Based Complement Alternat Med. 2020;2020:3259795.PubMedPubMedCentralCrossRef
124.
Elinav E, Nowarski R, Thaiss C, et al. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer. 2013;13:759–71.PubMedCrossRef
125.
Verma D, Bivik C, Farahani E, et al. Inflammasome polymorphisms confer susceptibility to sporadic malignant melanoma. Pigment Cell Melanoma Res. 2012;25(4):506–13.PubMedCrossRef
126.
Castano-Rodriguez N, Kaakoush NO, Goh KL, et al. The NOD-like receptor signalling pathway in Helicobacter pylori infection and related gastric cancer: a case-control study and gene expression analyses. PLoS ONE. 2014;9(6): e98899.PubMedPubMedCentralCrossRef
127.
Miskiewicz A, Szparecki G, Durlik M, et al. The Q705K and F359L single-nucleotide polymorphisms of NOD-like receptor signaling pathway: association with chronic pancreatitis, pancreatic cancer, and periodontitis. Arch Immunol Ther Exp. 2015;63(6):485–94.CrossRef
128.
Zhao X, Zhang C, Hua M, et al. NLRP3 inflammasome activation plays a carcinogenic role through effector cytokine IL-18 in lymphoma. Oncotarget. 2017;8(65):108571–83.PubMedPubMedCentralCrossRef
129.
Deswaerte V, Nguyen P, West A, et al. Inflammasome adaptor ASC suppresses apoptosis of gastric cancer cells by an IL18-mediated inflammation-independent mechanism. Cancer Res. 2018;78(5):1293–307.PubMedCrossRef
130.
Ikuta T, Kobayashi Y, Kitazawa M, et al. ASC-associated inflammation promotes cecal tumorigenesis in aryl hydrocarbon receptor-deficient mice. Carcinogenesis. 2013;34(7):1620–7.PubMedCrossRef
131.
Tu S, Bhagat G, Cui G, et al. Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. Cancer Cell. 2008;14(5):408–19.PubMedPubMedCentralCrossRef
132.
Chow MT, Sceneay J, Paget C, et al. NLRP3 suppresses NK cell-mediated responses to carcinogen-induced tumors and metastases. Cancer Res. 2012;72(22):5721–32.PubMedCrossRef
133.
Feng X, Luo Q, Zhang H, et al. The role of NLRP3 inflammasome in 5-fluorouracil resistance of oral squamous cell carcinoma. J Exp Clin Cancer Res. 2017;36(1):81.PubMedPubMedCentralCrossRef
134.
Wei Q, Mu K, Li T, et al. Deregulation of the NLRP3 inflammasome in hepatic parenchymal cells during liver cancer progression. Lab Invest. 2014;94(1):52–62.PubMedCrossRef
135.
Ojcius DM, Gasparoto TH, de Oliveira CE, et al. Inflammasome activation is critical to the protective immune response during chemically induced squamous cell carcinoma. PLoS ONE. 2014;9(9): e107170.CrossRef
136.
Allen IC, TeKippe EM, Woodford RM, et al. The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer. J Exp Med. 2010;207(5):1045–56.PubMedPubMedCentralCrossRef
137.
Zaki MH, Vogel P, Body-Malapel M, et al. IL-18 production downstream of the Nlrp3 inflammasome confers protection against colorectal tumor formation. J Immunol. 2010;185(8):4912–20.PubMedCrossRef
138.
Sharma D, Malik A, Guy CS, et al. Pyrin Inflammasome regulates tight junction integrity to restrict colitis and tumorigenesis. Gastroenterology. 2018;154(4):948–64.PubMedCrossRef
139.
Flood B, Manils J, Nulty C, et al. Caspase-11 regulates the tumour suppressor function of STAT1 in a murine model of colitis-associated carcinogenesis. Oncogene. 2019;38(14):2658–74.PubMedCrossRef
140.
Dagenais M, Dupaul-Chicoine J, Douglas T, et al. The interleukin (IL)-1R1 pathway is a critical negative regulator of PyMT-mediated mammary tumorigenesis and pulmonary metastasis. Oncoimmunology. 2017;6(3): e1287247.PubMedPubMedCentralCrossRef
141.
Hu B, Elinav E, Huber S, et al. Inflammation-induced tumorigenesis in the colon is regulated by caspase-1 and NLRC4. Proc Natl Acad Sci U S A. 2010;107(50):21635–40.PubMedPubMedCentralCrossRef
142.
Liu W, Luo Y, Dunn JH, et al. Dual role of apoptosis-associated speck-like protein containing a CARD (ASC) in tumorigenesis of human melanoma. J Invest Dermatol. 2013;133(2):518–27.PubMedCrossRef
143.
Drexler SK, Bonsignore L, Masin M, et al. Tissue-specific opposing functions of the inflammasome adaptor ASC in the regulation of epithelial skin carcinogenesis. Proc Natl Acad Sci U S A. 2012;109(45):18384–9.PubMedPubMedCentralCrossRef
144.
Gao J, Qiu X, Xi G, et al. Downregulation of GSDMD attenuates tumor proliferation via the intrinsic mitochondrial apoptotic pathway and inhibition of EGFR/Akt signaling and predicts a good prognosis in nonsmall cell lung cancer. Oncol Rep. 2018;40(4):1971–84.PubMedPubMedCentral
145.
Wang WJ, Chen D, Jiang MZ, et al. Downregulation of gasdermin D promotes gastric cancer proliferation by regulating cell cycle-related proteins. J Dig Dis. 2018;19(2):74–83.PubMedCrossRef
146.
147.
Yan H, Luo B, Wu X, et al. Cisplatin induces pyroptosis via activation of MEG3/NLRP3/caspase-1/GSDMD pathway in triple-negative breast cancer. Int J Biol Sci. 2021;17(10):2606–21.PubMedPubMedCentralCrossRef
148.
Wang L, Li K, Lin X, et al. Metformin induces human esophageal carcinoma cell pyroptosis by targeting the miR-497/PELP1 axis. Cancer Lett. 2019;450:22–31.PubMedCrossRef
149.
Yue E, Tuguzbaeva G, Chen X, et al. Anthocyanin is involved in the activation of pyroptosis in oral squamous cell carcinoma. Phytomedicine. 2019;56:286–94.PubMedCrossRef
150.
Sannino F, Sansone C, Galasso C, et al. Pseudoalteromonas haloplanktis TAC125 produces 4-hydroxybenzoic acid that induces pyroptosis in human A459 lung adenocarcinoma cells. Sci Rep. 2018;8(1):1190.PubMedPubMedCentralCrossRef
151.
Wang F, Liu W, Ning J, et al. Simvastatin suppresses proliferation and migration in non-small cell lung cancer via pyroptosis. Int J Biol Sci. 2018;14(4):406–17.PubMedPubMedCentralCrossRef
152.
Johnson DC, Taabazuing CY, Okondo MC, et al. DPP8/DPP9 inhibitor-induced pyroptosis for treatment of acute myeloid leukemia. Nat Med. 2018;24(8):1151–6.PubMedPubMedCentralCrossRef
153.
Pizato N, Luzete BC, Kiffer L, et al. Omega-3 docosahexaenoic acid induces pyroptosis cell death in triple-negative breast cancer cells. Sci Rep. 2018;8(1):1952.PubMedPubMedCentralCrossRef
154.
Nadeem S, Yang C, Du Y, et al. A virus-spike tumor-activatable pyroptotic agent. Small. 2021;17(8): e2006599.PubMedCrossRef
155.
Ploetz E, Zimpel A, Cauda V, et al. Metal-organic framework nanoparticles induce pyroptosis in cells controlled by the extracellular pH. Adv Mater. 2020;32(19): e1907267.PubMedCrossRef
156.
Qiao L, Wu X, Zhang J, et al. alpha-NETA induces pyroptosis of epithelial ovarian cancer cells through the GSDMD/caspase-4 pathway. FASEB J. 2019;33(11):12760–7.PubMedCrossRef
157.
158.
Serna N, Alamo P, Ramesh P, et al. Nanostructured toxins for the selective destruction of drug-resistant human CXCR4(+) colorectal cancer stem cells. J Control Release. 2020;320:96–104.PubMedCrossRef
159.
Yaw ACK, Chan EWL, Yap JKY, et al. The effects of NLRP3 inflammasome inhibition by MCC950 on LPS-induced pancreatic adenocarcinoma inflammation. J Cancer Res Clin Oncol. 2020;146(9):2219–29.PubMedCrossRef
160.
Viallard C, Larrivee B. Tumor angiogenesis and vascular normalization: alternative therapeutic targets. Angiogenesis. 2017;20(4):409–26.PubMedCrossRef
161.
162.
163.
Van Gorp H, Lamkanfi M. The emerging roles of inflammasome-dependent cytokines in cancer development. EMBO Rep. 2019;20(6):e47575.PubMedPubMedCentral
164.
Saijo Y, Tanaka M, Miki M, et al. Proinflammatory cytokine IL-1 beta promotes tumor growth of Lewis lung carcinoma by induction of angiogenic factors: in vivo analysis of tumor-stromal interaction. J Immunol. 2002;169(1):469–75.PubMedCrossRef
165.
Jung YJ, Isaacs JS, Lee S, et al. IL-1beta-mediated up-regulation of HIF-1alpha via an NFkappaB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. FASEB J. 2003;17(14):2115–7.PubMedCrossRef
166.
167.
Carmi Y, Voronov E, Dotan S, et al. The role of macrophage-derived IL-1 in induction and maintenance of angiogenesis. J Immunol. 2009;183(7):4705–14.PubMedCrossRef
168.
169.
Carmi Y, Dotan S, Rider P, et al. The role of IL-1beta in the early tumor cell-induced angiogenic response. J Immunol. 2013;190(7):3500–9.PubMedCrossRef
170.
Kong H, Wang Y, Zeng X, et al. Differential expression of inflammasomes in lung cancer cell lines and tissues. Tumour Biol. 2015;36(10):7501–13.PubMedCrossRef
171.
Poli G, Brancorsini S, Cochetti G, et al. Expression of inflammasome-related genes in bladder cancer and their association with cytokeratin 20 messenger RNA. Urol Oncol. 2015;33(12):505.CrossRef
172.
Lee HE, Lee JY, Yang G, et al. Inhibition of NLRP3 inflammasome in tumor microenvironment leads to suppression of metastatic potential of cancer cells. Sci Rep. 2019;9(1):12277.PubMedPubMedCentralCrossRef
173.
Bent R, Moll L, Grabbe S, et al. Interleukin-1 beta-a friend or foe in malignancies? Int J Mol Sci. 2018;19(8):2155.CrossRef
174.
Horio D, Minami T, Kitai H, et al. Tumor-associated macrophage-derived inflammatory cytokine enhances malignant potential of malignant pleural mesothelioma. Cancer Sci. 2020;111(8):2895–906.PubMedPubMedCentralCrossRef
175.
Jin H, Ko YS, Kim HJ. P2Y2R-mediated inflammasome activation is involved in tumor progression in breast cancer cells and in radiotherapy-resistant breast cancer. Int J Oncol. 2018;53(5):1953–66.PubMedPubMedCentral
176.
Genin M, Clement F, Fattaccioli A, et al. M1 and M2 macrophages derived from THP-1 cells differentially modulate the response of cancer cells to etoposide. BMC Cancer. 2015;15:577.PubMedPubMedCentralCrossRef
177.
Li Y, Cao F, Li M, et al. Hydroxychloroquine induced lung cancer suppression by enhancing chemo-sensitization and promoting the transition of M2-TAMs to M1-like macrophages. J Exp Clin Cancer Res. 2018;37(1):259.CrossRef
178.
Yang D, Cao X, Wang F, et al. LFG-500, a novel synthetic flavonoid, suppresses epithelial-mesenchymal transition in human lung adenocarcinoma cells by inhibiting NLRP3 in inflammatory microenvironment. Cancer Lett. 2017;400:137–48.PubMedCrossRef
179.
Tulotta C, Lefley DV, Freeman K, et al. Endogenous production of IL1B by breast cancer cells drives metastasis and colonization of the bone microenvironment. Clin Cancer Res. 2019;25(9):2769–82.PubMedCrossRef
180.
Matsumoto R, Tsuda M, Yoshida K, et al. Aldo-keto reductase 1C1 induced by interleukin-1beta mediates the invasive potential and drug resistance of metastatic bladder cancer cells. Sci Rep. 2016;6:34625.PubMedPubMedCentralCrossRef
181.
Zhang Y, Yang H, Sun M, et al. Alpinumisoflavone suppresses hepatocellular carcinoma cell growth and metastasis via NLRP3 inflammasome-mediated pyroptosis. Pharmacol Rep. 2020;72(5):1370–82.PubMedCrossRef
182.
Dupaul-Chicoine J, Arabzadeh A, Dagenais M, et al. The Nlrp3 inflammasome suppresses colorectal cancer metastatic growth in the liver by promoting natural killer cell tumoricidal activity. Immunity. 2015;43(4):751–63.PubMedCrossRef
183.
Deng Q, Geng Y, Zhao L, et al. NLRP3 inflammasomes in macrophages drive colorectal cancer metastasis to the liver. Cancer Lett. 2019;442:21–30.PubMedCrossRef
184.
Xu Y, Li H, Chen W, et al. Mycoplasma hyorhinis activates the NLRP3 inflammasome and promotes migration and invasion of gastric cancer cells. PLoS ONE. 2013;8(11): e77955.PubMedPubMedCentralCrossRef
185.
Huang Q, Lan F, Wang X, et al. IL-1β-induced activation of p38 promotes metastasis in gastric adenocarcinoma via upregulation of AP-1/c-fos, MMP2 and MMP9. Mol Cancer. 2014;13:18.PubMedPubMedCentralCrossRef
186.
Zhang D, Jiang Q, Ge X, et al. RHOV promotes lung adenocarcinoma cell growth and metastasis through JNK/c-Jun pathway. Int J Biol Sci. 2021;17(10):2622–32.PubMedPubMedCentralCrossRef
187.
Wang JF, Zhao K, Chen YY, et al. NKCC1 promotes proliferation, invasion and migration in human gastric cancer cells via activation of the MAPK-JNK/EMT signaling pathway. J Cancer. 2021;12(1):253–63.PubMedPubMedCentralCrossRef
188.
Chen Q, Lei JH, Bao J, et al. BRCA1 deficiency impairs mitophagy and promotes inflammasome activation and mammary tumor metastasis. Adv Sci. 2020;7(6):1903616.CrossRef
189.
Perez-Yepez EA, Ayala-Sumuano JT, Lezama R, et al. A novel beta-catenin signaling pathway activated by IL-1beta leads to the onset of epithelial-mesenchymal transition in breast cancer cells. Cancer Lett. 2014;354(1):164–71.PubMedCrossRef
190.
Jeon M, Han J, Nam SJ, et al. Elevated IL-1beta expression induces invasiveness of triple negative breast cancer cells and is suppressed by zerumbone. Chem Biol Interact. 2016;258:126–33.PubMedCrossRef
191.
Wang Y, Kong H, Zeng X, et al. Activation of NLRP3 inflammasome enhances the proliferation and migration of A549 lung cancer cells. Oncol Rep. 2016;35(4):2053–64.PubMedCrossRef
192.
Ohashi K, Wang Z, Yang YM, et al. NOD-like receptor C4 inflammasome regulates the growth of colon cancer liver metastasis in NAFLD. Hepatology. 2019;70(5):1582–99.PubMedCrossRef
193.
Farshchian M, Nissinen L, Siljamäki E, et al. Tumor cell-specific AIM2 regulates growth and invasion of cutaneous squamous cell carcinoma. Oncotarget. 2017;8(28):45825–36.PubMedPubMedCentralCrossRef
194.
Wang Y, Li Z, Teng M, et al. Dihydroartemisinin inhibits activation of the AIM2 inflammasome pathway and NF-kappaB/HIF-1alpha/VEGF pathway by inducing autophagy in A431 human cutaneous squamous cell carcinoma cells. Int J Med Sci. 2021;18(12):2705–15.PubMedPubMedCentralCrossRef
195.
Chai D, Shan H, Wang G, et al. AIM2 is a potential therapeutic target in human renal carcinoma and suppresses its invasion and metastasis via enhancing autophagy induction. Exp Cell Res. 2018;370(2):561–70.PubMedCrossRef
196.
Chai D, Zhang Z, Shi SY, et al. Absent in melanoma 2-mediating M1 macrophages facilitate tumor rejection in renal carcinoma. Transl Oncol. 2021;14(4): 101018.PubMedPubMedCentralCrossRef
197.
Cervantes-Villagrana RD, Albores-Garcia D, Cervantes-Villagrana AR, et al. Tumor-induced neurogenesis and immune evasion as targets of innovative anti-cancer therapies. Signal Transduct Target Ther. 2020;5(1):99.PubMedPubMedCentralCrossRef
198.
Reeves E, James E. Antigen processing and immune regulation in the response to tumours. Immunology. 2017;150(1):16–24.PubMedCrossRef
199.
Theivanthiran B, Evans KS, DeVito NC, et al. A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti-PD-1 immunotherapy. J Clin Invest. 2020;130(5):2570–86.PubMedPubMedCentralCrossRef
200.
Lasithiotaki I, Tsitoura E, Samara KD, et al. NLRP3/Caspase-1 inflammasome activation is decreased in alveolar macrophages in patients with lung cancer. PLoS ONE. 2018;13(10): e0205242.PubMedPubMedCentralCrossRef
201.
202.
Tengesdal IW, Dinarello A, Powers NE, et al. Tumor NLRP3-derived IL-1beta Drives the IL-6/STAT3 axis resulting in sustained MDSC-mediated immunosuppression. Front Immunol. 2021;12: 661323.PubMedPubMedCentralCrossRef
203.
Chen L, Huang CF, Li YC, et al. Blockage of the NLRP3 inflammasome by MCC950 improves anti-tumor immune responses in head and neck squamous cell carcinoma. Cell Mol Life Sci. 2018;75(11):2045–58.PubMedCrossRef
204.
van Deventer HW, Burgents JE, Wu QP, et al. The inflammasome component NLRP3 impairs antitumor vaccine by enhancing the accumulation of tumor-associated myeloid-derived suppressor cells. Cancer Res. 2010;70(24):10161–9.PubMedPubMedCentralCrossRef
205.
Nakamura K, Kassem S, Cleynen A, et al. Dysregulated IL-18 is a key driver of immunosuppression and a possible therapeutic target in the multiple myeloma microenvironment. Cancer Cell. 2018;33(4):634–48.PubMedCrossRef
206.
Ghiringhelli F, Apetoh L, Tesniere A, et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med. 2009;15(10):1170–8.PubMedCrossRef
207.
208.
Lu F, Zhao Y, Pang Y, et al. NLRP3 inflammasome upregulates PD-L1 expression and contributes to immune suppression in lymphoma. Cancer Lett. 2021;497:178–89.PubMedCrossRef
209.
Timperi E, Focaccetti C, Gallerano D, et al. IL-18 receptor marks functional CD8+ T cells in non-small cell lung cancer. OncoImmunology. 2017;6(7):e1328337.PubMedPubMedCentralCrossRef
210.
Li XY, Moesta AK, Xiao C, et al. Targeting CD39 in cancer reveals an extracellular ATP- and inflammasome-driven tumor immunity. Cancer Discov. 2019;9(12):1754–73.PubMedPubMedCentralCrossRef
211.
Dmitrieva-Posocco O, Dzutsev A, Posocco DF, et al. Cell-type-specific responses to interleukin-1 control microbial invasion and tumor-elicited inflammation in colorectal cancer. Immunity. 2019;50(1):166–80.PubMedPubMedCentralCrossRef
212.
Sauter KA, Wood LJ, Wong J, et al. Doxorubicin and daunorubicin induce processing and release of interleukin-1beta through activation of the NLRP3 inflammasome. Cancer Biol Ther. 2011;11(12):1008–16.PubMedPubMedCentralCrossRef
213.
Wong J, Tran LT, Magun EA, et al. Production of IL-1beta by bone marrow-derived macrophages in response to chemotherapeutic drugs: synergistic effects of doxorubicin and vincristine. Cancer Biol Ther. 2014;15(10):1395–403.PubMedPubMedCentralCrossRef
214.
Voloshin T, Alishekevitz D, Kaneti L, et al. Blocking IL1beta pathway following paclitaxel chemotherapy slightly inhibits primary tumor growth but promotes spontaneous metastasis. Mol Cancer Ther. 2015;14(6):1385–94.PubMedCrossRef
215.
216.
Tang Z, Ji L, Han M, et al. Pyroptosis is involved in the inhibitory effect of FL118 on growth and metastasis in colorectal cancer. Life Sci. 2020;257: 118065.PubMedCrossRef
217.
Huang Y, Wang H, Hao Y, et al. Myeloid PTEN promotes chemotherapy-induced NLRP3-inflammasome activation and antitumour immunity. Nat Cell Biol. 2020;22(6):716–27.PubMedCrossRef
218.
Zheng Q, Yao D, Cai Y, et al. NLRP3 augmented resistance to gemcitabine in triple-negative breast cancer cells via EMT/IL-1beta/Wnt/beta-catenin signaling pathway. Biosci Rep. 2020;40(7).
219.
Zeng QZ, Yang F, Li CG, et al. Paclitaxel enhances the innate immunity by promoting NLRP3 inflammasome activation in macrophages. Front Immunol. 2019;10:72.PubMedPubMedCentralCrossRef
220.
De Ruysscher D, Niedermann G, Burnet NG, et al. Radiotherapy toxicity. Nat Rev Dis Primers. 2019;5(1):13.PubMedCrossRef
221.
Wei J, Wang H, Wang H, et al. The role of NLRP3 inflammasome activation in radiation damage. Biomed Pharmacother. 2019;118: 109217.PubMedCrossRef
222.
Zhang Q, Hu Q, Chu Y, et al. The influence of radiotherapy on AIM2 inflammasome in radiation pneumonitis. Inflammation. 2016;39(5):1827–34.PubMedCrossRef
223.
Christersdottir Björklund T, Pirault J, Gisterå A, et al. Prevention of radiotherapy-induced arterial inflammation by interleukin-1 blockade. Eur Heart J. 2019;40(30):2495–503.CrossRef
224.
Gao J, Peng S, Shan X, et al. Inhibition of AIM2 inflammasome-mediated pyroptosis by Andrographolide contributes to amelioration of radiation-induced lung inflammation and fibrosis. Cell Death Dis. 2019;10(12):957.PubMedPubMedCentralCrossRef
225.
Fernandez-Gil B, Moneim AE, Ortiz F, et al. Melatonin protects rats from radiotherapy-induced small intestine toxicity. PLoS ONE. 2017;12(4): e0174474.PubMedPubMedCentralCrossRef
226.
Xiao J, Wang C, Yao JC, et al. Radiation causes tissue damage by dysregulating inflammasome-gasdermin D signaling in both host and transplanted cells. PLoS Biol. 2020;18(8): e3000807.PubMedPubMedCentralCrossRef
227.
Liu YG, Chen JK, Zhang ZT, et al. NLRP3 inflammasome activation mediates radiation-induced pyroptosis in bone marrow-derived macrophages. Cell Death Dis. 2017;8(2): e2579.PubMedPubMedCentralCrossRef
228.
Sun H, Cai H, Fu Y, et al. The protection effect of resveratrol against radiation-induced inflammatory bowel disease via NLRP-3 inflammasome repression in mice. Dose Response. 2020;18(2):1559325820931292.PubMedPubMedCentralCrossRef
229.
Wu M, Shi J, He S, et al. cGAS promotes sepsis in radiotherapy of cancer by up-regulating caspase-11 signaling. Biochem Biophys Res Commun. 2021;551:86–92.PubMedCrossRef
230.
Sohn SH, Lee JM, Park S, et al. The inflammasome accelerates radiation-induced lung inflammation and fibrosis in mice. Environ Toxicol Pharmacol. 2015;39(2):917–26.PubMedCrossRef
231.
Golden EB, Apetoh L. Radiotherapy and immunogenic cell death. Semin Radiat Oncol. 2015;25(1):11–7.PubMedCrossRef
232.
233.
Ma Y, Kepp O, Ghiringhelli F, et al. Chemotherapy and radiotherapy: cryptic anticancer vaccines. Semin Immunol. 2010;22(3):113–24.PubMedCrossRef
234.
Jin H, Kim HJ. NLRC4, ASC and caspase-1 are inflammasome components that are mediated by P2Y2R activation in breast cancer cells. Int J Mol Sci. 2020;21(9):3337.PubMedPubMedCentralCrossRef
235.
Young HL, Rowling EJ, Bugatti M, et al. An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition. J Exp Med. 2017;214(6):1691–710.PubMedPubMedCentralCrossRef
236.
Hajek E, Krebs F, Bent R, et al. BRAF inhibitors stimulate inflammasome activation and interleukin 1 beta production in dendritic cells. Oncotarget. 2018;9(47):28294–308.PubMedPubMedCentralCrossRef
237.
Abbate A, Toldo S, Marchetti C, et al. Interleukin-1 and the inflammasome as therapeutic targets in cardiovascular disease. Circ Res. 2020;126(9):1260–80.PubMedPubMedCentralCrossRef
238.
Dinarello CA. The IL-1 family of cytokines and receptors in rheumatic diseases. Nat Rev Rheumatol. 2019;15(10):612–32.PubMedCrossRef
239.
240.
Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119–31.PubMedCrossRef
241.
242.
Grebe A, Hoss F, Latz E. NLRP3 inflammasome and the IL-1 pathway in atherosclerosis. Circ Res. 2018;122(12):1722–40.PubMedCrossRef
243.
Martinez GJ, Celermajer DS, Patel S. The NLRP3 inflammasome and the emerging role of colchicine to inhibit atherosclerosis-associated inflammation. Atherosclerosis. 2018;269:262–71.PubMedCrossRef
244.
Lusebrink E, Goody PR, Lahrmann C, et al. AIM2 stimulation impairs reendothelialization and promotes the development of atherosclerosis in mice. Front Cardiovasc Med. 2020;7: 582482.PubMedPubMedCentralCrossRef
245.
Tengesdal IW, Menon DR, Osborne DG, et al. Targeting tumor-derived NLRP3 reduces melanoma progression by limiting MDSCs expansion. Proc Natl Acad Sci U S A. 2021;118(10):e2000915118.PubMedPubMedCentralCrossRef
246.
Coll RC, Robertson AA, Chae JJ, et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med. 2015;21(3):248–55.PubMedPubMedCentralCrossRef
247.
Coll RC, Hill JR, Day CJ, et al. MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition. Nat Chem Biol. 2019;15(6):556–9.PubMedCrossRef
248.
Tapia-Abellan A, Angosto-Bazarra D, Martinez-Banaclocha H, et al. MCC950 closes the active conformation of NLRP3 to an inactive state. Nat Chem Biol. 2019;15(6):560–4.PubMedPubMedCentralCrossRef
249.
Jiang H, He H, Chen Y, et al. Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders. J Exp Med. 2017;214(11):3219–38.PubMedPubMedCentralCrossRef
250.
251.
Darakhshan S, Pour AB. Tranilast: a review of its therapeutic applications. Pharmacol Res. 2015;91:15–28.PubMedCrossRef
252.
Takahashi K, Menju T, Nishikawa S, et al. Tranilast inhibits TGF-beta1-induced epithelial-mesenchymal transition and invasion/metastasis via the suppression of smad4 in human lung cancer cell lines. Anticancer Res. 2020;40(6):3287–96.PubMedCrossRef
253.
Saito H, Fushida S, Harada S, et al. Importance of human peritoneal mesothelial cells in the progression, fibrosis, and control of gastric cancer: inhibition of growth and fibrosis by tranilast. Gastric Cancer. 2018;21(1):55–67.PubMedCrossRef
254.
He Y, Varadarajan S, Muñoz-Planillo R, et al. 3,4-methylenedioxy-β-nitrostyrene inhibits NLRP3 inflammasome activation by blocking assembly of the inflammasome. J Biol Chem. 2014;289(2):1142–50.PubMedCrossRef
255.
256.
Honda H, Nagai Y, Matsunaga T, et al. Isoliquiritigenin is a potent inhibitor of NLRP3 inflammasome activation and diet-induced adipose tissue inflammation. J Leukoc Biol. 2014;96(6):1087–100.PubMedCrossRef
257.
Liu X, Pichulik T, Wolz OO, et al. Human NACHT, LRR, and PYD domain-containing protein 3 (NLRP3) inflammasome activity is regulated by and potentially targetable through Bruton tyrosine kinase. J Allergy Clin Immunol. 2017;140(4):1054–67.PubMedCrossRef
258.
Tian X, Zhang S, Zhang Q, et al. Resveratrol inhibits tumor progression by down-regulation of NLRP3 in renal cell carcinoma. J Nutr Biochem. 2020;85: 108489.PubMedCrossRef
259.
Maayah ZH, Alam AS, Takahara S, et al. Resveratrol reduces cardiac NLRP3-inflammasome activation and systemic inflammation to lessen doxorubicin-induced cardiotoxicity in juvenile mice. FEBS Lett. 2021;595(12):1681–95.PubMedPubMedCentralCrossRef
260.
Liu Q, Guo X, Huang Z, et al. Anti-neuroinflammatory effects of dimethylaminomylide (DMAMCL, i.e., ACT001) are associated with attenuating the NLRP3 in fl ammasome in MPTP-induced Parkinson disease in mice. Behav Brain Res. 2020;383:112539.PubMedCrossRef
261.
262.
Lee J, Ahn H, Hong EJ, et al. Sulforaphane attenuates activation of NLRP3 and NLRC4 inflammasomes but not AIM2 inflammasome. Cell Immunol. 2016;306–307:53–60.PubMedCrossRef
263.
Teng JF, Mei QB, Zhou XG, et al. Polyphyllin VI induces caspase-1-mediated pyroptosis via the induction of ROS/NF-kappaB/NLRP3/GSDMD signal axis in non-small cell lung cancer. Cancers. 2020;12(1):193.PubMedPubMedCentralCrossRef
264.
Zhang M, Jin C, Yang Y, et al. AIM2 promotes non-small-cell lung cancer cell growth through inflammasome-dependent pathway. J Cell Physiol. 2019;234(11):20161–73.PubMedCrossRef
265.
Wei Q, Zhu R, Zhu J, et al. E2-induced activation of the NLRP3 inflammasome triggers pyroptosis and inhibits autophagy in HCC cells. Oncol Res. 2019;27(7):827–34.PubMedPubMedCentralCrossRef
266.
Winter RN, Rhee JG, Kyprianou N. Caspase-1 enhances the apoptotic response of prostate cancer cells to ionizing radiation. Anticancer Res. 2004;24(3a):1377–86.PubMed
267.
Zeng Q, Fu J, Korrer M, et al. Caspase-1 from human myeloid-derived suppressor cells can promote T cell-independent tumor proliferation. Cancer Immunol Res. 2018;6(5):566–77.PubMedPubMedCentralCrossRef
268.
Salvucci O, Carsana M, Bersani I, et al. Antiapoptotic role of endogenous nitric oxide in human melanoma cells. Cancer Res. 2001;61(1):318–26.PubMed
269.
Kobori M, Iwashita K, Shinmoto H, et al. Phloretin-induced apoptosis in B16 melanoma 4A5 cells and HL60 human leukemia cells. Biosci Biotechnol Biochem. 1999;63(4):719–25.PubMedCrossRef
270.
Chen YQ, Wang SN, Shi YJ, et al. CRID3, a blocker of apoptosis associated speck like protein containing a card, ameliorates murine spinal cord injury by improving local immune microenvironment. J Neuroinflamm. 2020;17(1):255.CrossRef
271.
Coll RC, Robertson A, Butler M, et al. The cytokine release inhibitory drug CRID3 targets ASC oligomerisation in the NLRP3 and AIM2 inflammasomes. PLoS ONE. 2011;6(12): e29539.PubMedPubMedCentralCrossRef
272.
Sollberger G, Choidas A, Burn GL, et al. Gasdermin D plays a vital role in the generation of neutrophil extracellular traps. Sci Immunol. 2018;3(26):eaar6689.PubMedCrossRef
273.
Silva CM, Wanderley CW, Veras FP, et al. Gasdermin D inhibition prevents multiple organ dysfunction during sepsis by blocking NET formation. Blood. 2021;138(25):2702–13.PubMedPubMedCentralCrossRef
274.
Hu JJ, Liu X, Zhao J, et al. Identification of pyroptosis inhibitors that target a reactive cysteine in gasdermin D. 2018.
275.
Li Y, Chen F, Chen J, et al. Disulfiram/copper induces antitumor activity against both nasopharyngeal cancer cells and cancer-associated fibroblasts through ROS/MAPK and ferroptosis Pathways. Cancers. 2020;12(1):138.PubMedPubMedCentralCrossRef
276.
Wang Y, Zhang XL, Sun CM. BAY-11-7082 induces apoptosis of multiple myeloma U266 cells through inhibiting NF-κB pathway. Eur Rev Med Pharmacol Sci. 2018;22(9):2564–71.PubMed
277.
Dai Y, Pei XY, Rahmani M, et al. Interruption of the NF-kappaB pathway by bay 11–7082 promotes UCN-01-mediated mitochondrial dysfunction and apoptosis in human multiple myeloma cells. Blood. 2004;103(7):2761–70.PubMedCrossRef
278.
Alten R, Gram H, Joosten LA, et al. The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis. Arthritis Res Ther. 2008;10(3):R67.PubMedPubMedCentralCrossRef
279.
Economides AN, Carpenter LR, Rudge JS, et al. Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nat Med. 2003;9(1):47–52.PubMedCrossRef
280.
281.
Harouki N, Nicol L, Remy-Jouet I, et al. The IL-1beta antibody gevokizumab limits cardiac remodeling and coronary dysfunction in rats with heart failure. JACC Basic Transl Sci. 2017;2(4):418–30.PubMedPubMedCentralCrossRef
282.
283.
Voigt C, May P, Gottschlich A, et al. Cancer cells induce interleukin-22 production from memory CD4(+) T cells via interleukin-1 to promote tumor growth. Proc Natl Acad Sci USA. 2017;114(49):12994–9.PubMedPubMedCentralCrossRef
284.
Ridker PM, MacFadyen JG, Thuren T, et al. Effect of interleukin-1beta inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390(10105):1833–42.PubMedCrossRef
285.
Wong CC, Baum J, Silvestro A, et al. Inhibition of IL1beta by canakinumab may be effective against diverse molecular subtypes of lung cancer: an exploratory analysis of the CANTOS trial. Cancer Res. 2020;80(24):5597–605.PubMedCrossRef
286.
O’Shaughnessy J, Young RR, Levin MK, et al. Safety and immunologic activity of anakinra in HER2-negative metastatic breast cancer (MBC). J Clin Oncol. 2016;34(15_suppl):e14565–665.CrossRef
287.
Wardill HR, de Mooij CEM, Da Silva Ferreira AR, et al. Supporting the gastrointestinal microenvironment during high-dose chemotherapy and stem cell transplantation by inhibiting IL-1 signaling with anakinra. Sci Rep. 2022;12(1):6803.PubMedPubMedCentralCrossRef
288.
Isambert N, Hervieu A, Rebe C, et al. Fluorouracil and bevacizumab plus anakinra for patients with metastatic colorectal cancer refractory to standard therapies (IRAFU): a single-arm phase 2 study. Oncoimmunology. 2018;7(9): e1474319.PubMedPubMedCentralCrossRef
289.
Giavridis T, van der Stegen SJC, Eyquem J, et al. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat Med. 2018;24(6):731–8.PubMedPubMedCentralCrossRef
290.
Wei Q, Guo P, Mu K, et al. Estrogen suppresses hepatocellular carcinoma cells through ERbeta-mediated upregulation of the NLRP3 inflammasome. Lab Invest. 2015;95(7):804–16.PubMedCrossRef
291.
Raut PK, Kim SH, Choi DY, et al. Growth of breast cancer cells by leptin is mediated via activation of the inflammasome: critical roles of estrogen receptor signaling and reactive oxygen species production. Biochem Pharmacol. 2019;161:73–88.PubMedCrossRef
292.
293.
294.
Ariffin JK, Sweet MJ. Differences in the repertoire, regulation and function of Toll-like receptors and inflammasome-forming nod-like receptors between human and mouse. Curr Opin Microbiol. 2013;16(3):303–10.PubMedCrossRef
295.
Atianand MK, Duffy EB, Shah A, et al. Francisella tularensis reveals a disparity between human and mouse NLRP3 inflammasome activation. J Biol Chem. 2011;286(45):39033–42.PubMedPubMedCentralCrossRef
296.
Chow MT, Tschopp J, Möller A, et al. NLRP3 promotes inflammation-induced skin cancer but is dispensable for asbestos-induced mesothelioma. Immunol Cell Biol. 2012;90(10):983–6.PubMedCrossRef
297.
Mori N, Yamada Y, Ikeda S, et al. Bay 11–7082 inhibits transcription factor NF-kappaB and induces apoptosis of HTLV-I-infected T-cell lines and primary adult T-cell leukemia cells. Blood. 2002;100(5):1828–34.PubMedCrossRef
298.
Chen L, Ruan Y, Wang X, et al. BAY 11–7082, a nuclear factor-kappaB inhibitor, induces apoptosis and S phase arrest in gastric cancer cells. J Gastroenterol. 2014;49(5):864–74.PubMedCrossRef
299.
Zhao J, Zhang H, Huang Y, et al. Bay11-7082 attenuates murine lupus nephritis via inhibiting NLRP3 inflammasome and NF-kappaB activation. Int Immunopharmacol. 2013;17(1):116–22.PubMedCrossRef
300.
Irrera N, Vaccaro M, Bitto A, et al. BAY 11–7082 inhibits the NF-kappaB and NLRP3 inflammasome pathways and protects against IMQ-induced psoriasis. Clin Sci. 2017;131(6):487–98.CrossRef
301.
Chen S, Wang Y, Pan Y, et al. Novel role for tranilast in regulating NLRP3 ubiquitination, vascular inflammation, and atherosclerosis. J Am Heart Assoc. 2020;9(12): e015513.PubMedPubMedCentralCrossRef
302.
Lonnemann N, Hosseini S, Marchetti C, et al. The NLRP3 inflammasome inhibitor OLT1177 rescues cognitive impairment in a mouse model of Alzheimer’s disease. Proc Natl Acad Sci U S A. 2020;117(50):32145–54.PubMedPubMedCentralCrossRef
303.
Lunding LP, Skouras DB, Vock C, et al. The NLRP3 inflammasome inhibitor, OLT1177((R)), ameliorates experimental allergic asthma in mice. Allergy. 2022;77(3):1035-38.PubMedCrossRef
304.
Wang X, Sun K, Zhou Y, et al. NLRP3 inflammasome inhibitor CY-09 reduces hepatic steatosis in experimental NAFLD mice. Biochem Biophys Res Commun. 2021;534:734–9.PubMedCrossRef
305.
Zhang Y, Lin Z, Chen D, et al. CY-09 attenuates the progression of osteoarthritis via inhibiting NLRP3 inflammasome-mediated pyroptosis. Biochem Biophys Res Commun. 2021;553:119–25.PubMedCrossRef
306.
Liu H, Xu Y, Liang K, et al. Immune cells combined with NLRP3 inflammasome inhibitor exert better antitumor effect on pancreatic ductal adenocarcinoma. Front Oncol. 2020;10:1378.PubMedPubMedCentralCrossRef
307.
Chen IH, Chang FR, Wu YC, et al. 3,4-Methylenedioxy-beta-nitrostyrene inhibits adhesion and migration of human triple-negative breast cancer cells by suppressing beta1 integrin function and surface protein disulfide isomerase. Biochimie. 2015;110:81–92.PubMedCrossRef
308.
Xiao M, Li L, Li C, et al. 3,4-methylenedioxy-beta-nitrostyrene ameliorates experimental burn wound progression by inhibiting the NLRP3 inflammasome activation. Plast Reconstr Surg. 2016;137(3):566e-e575.PubMedCrossRef
309.
Xu L, Bi Y, Xu Y, et al. Oridonin inhibits the migration and epithelial-to-mesenchymal transition of small cell lung cancer cells by suppressing FAK-ERK1/2 signalling pathway. J Cell Mol Med. 2020;24(8):4480–93.PubMedPubMedCentralCrossRef
310.
Yang J, Ren X, Zhang L, et al. Oridonin inhibits oral cancer growth and PI3K/Akt signaling pathway. Biomed Pharmacother. 2018;100:226–32.PubMedCrossRef
311.
Li M, Liu H, Shao H, et al. Glyburide attenuates B(a)p and LPS-induced inflammation-related lung tumorigenesis in mice. Environ Toxicol. 2021;36(8):1713–22.PubMedCrossRef
312.
Shim DW, Shin WY, Yu SH, et al. BOT-4-one attenuates NLRP3 inflammasome activation: NLRP3 alkylation leading to the regulation of its ATPase activity and ubiquitination. Sci Rep. 2017;7(1):15020.PubMedPubMedCentralCrossRef
313.
Kim BH, Min YS, Choi JS, et al. Benzoxathiol derivative BOT-4-one suppresses L540 lymphoma cell survival and proliferation via inhibition of JAK3/STAT3 signaling. Exp Mol Med. 2011;43(5):313–21.PubMedPubMedCentralCrossRef
314.
Lin ZH, Wang SY, Chen LL, et al. Methylene blue mitigates acute neuroinflammation after spinal cord injury through inhibiting nlrp3 inflammasome activation in microglia. Front Cell Neurosci. 2017;11:391.PubMedPubMedCentralCrossRef
315.
Yi HJ, Lee JE, Lee DH, et al. The role of NLRP3 in traumatic brain injury and its regulation by pioglitazone. J Neurosurg. 2019;1–9.
316.
Daniels MJ, Rivers-Auty J, Schilling T, et al. Fenamate NSAIDs inhibit the NLRP3 inflammasome and protect against Alzheimer’s disease in rodent models. Nat Commun. 2016;7:12504.PubMedPubMedCentralCrossRef
317.
Guo C, Fulp JW, Jiang Y, et al. Development and characterization of a hydroxyl-sulfonamide analogue, 5-chloro-N-[2-(4-hydroxysulfamoyl-phenyl)-ethyl]-2-methoxy-benzamide, as a Novel NLRP3 inflammasome inhibitor for potential treatment of multiple sclerosis. ACS Chem Neurosci. 2017;8(10):2194–201.PubMedCrossRef
318.
Yin J, Zhao F, Chojnacki JE, et al. NLRP3 inflammasome inhibitor ameliorates amyloid pathology in a mouse model of alzheimer’s disease. Mol Neurobiol. 2018;55(3):1977–87.PubMedCrossRef
319.
Awad AS, Elariny HA, Sallam AS. The possible protective effect of colchicine against liver damage induced by renal ischemia-reperfusion injury: role of Nrf2 and NLRP3 inflammasome. Can J Physiol Pharmacol. 2020;98(12):849–54.PubMedCrossRef
320.
Shi Y, Lv Q, Zheng M, et al. NLRP3 inflammasome inhibitor INF39 attenuated NLRP3 assembly in macrophages. Int Immunopharmacol. 2021;92: 107358.PubMedCrossRef
321.
Liu F, Liu T, Sun M, et al. Maxing shigan decoction mitigates mycoplasma pneumonia-induced pyroptosis in A549 cells via the NLRP3 inflammasome. Infect Drug Resist. 2021;14:859–67.PubMedPubMedCentralCrossRef
322.
Gong Y, Cao X, Gong L, et al. Sulforaphane alleviates retinal ganglion cell death and inflammation by suppressing NLRP3 inflammasome activation in a rat model of retinal ischemia/reperfusion injury. Int J Immunopathol Pharmacol. 2019;33:2058738419861777.PubMedPubMedCentralCrossRef
323.
Shang S, Wang L, Zhang Y, et al. The beta-hydroxybutyrate suppresses the migration of glioma cells by inhibition of NLRP3 inflammasome. Cell Mol Neurobiol. 2018;38(8):1479–89.PubMedCrossRef
324.
Shippy DC, Wilhelm C, Viharkumar PA, et al. beta-Hydroxybutyrate inhibits inflammasome activation to attenuate Alzheimer’s disease pathology. J Neuroinflamm. 2020;17(1):280.CrossRef
325.
Goldberg EL, Asher JL, Molony RD, et al. beta-hydroxybutyrate deactivates neutrophil NLRP3 inflammasome to relieve gout flares. Cell Rep. 2017;18(9):2077–87.PubMedPubMedCentralCrossRef
326.
Carbone S, Mauro AG, Prestamburgo A, et al. An orally available NLRP3 inflammasome inhibitor prevents western diet-induced cardiac dysfunction in mice. J Cardiovasc Pharmacol. 2018;72(6):303–7.PubMedPubMedCentralCrossRef
327.
Marchetti C, Chojnacki J, Toldo S, et al. A novel pharmacologic inhibitor of the NLRP3 inflammasome limits myocardial injury after ischemia-reperfusion in the mouse. J Cardiovasc Pharmacol. 2014;63(4):316–22.PubMedPubMedCentralCrossRef
328.
329.
Lim H, Min DS, Park H, et al. Flavonoids interfere with NLRP3 inflammasome activation. Toxicol Appl Pharmacol. 2018;355:93–102.PubMedCrossRef
330.
Liu W, Guo W, Wu J, et al. A novel benzo[d]imidazole derivate prevents the development of dextran sulfate sodium-induced murine experimental colitis via inhibition of NLRP3 inflammasome. Biochem Pharmacol. 2013;85(10):1504–12.PubMedCrossRef
331.
Wu D, Wu K, Zhu Q, et al. Formononetin administration ameliorates dextran sulfate sodium-induced acute colitis by inhibiting NLRP3 inflammasome signaling pathway. Mediat Inflamm. 2018;2018:1–12.
332.
Li R, Lu K, Wang Y, et al. Triptolide attenuates pressure overload-induced myocardial remodeling in mice via the inhibition of NLRP3 inflammasome expression. Biochem Biophys Res Commun. 2017;485(1):69–75.PubMedCrossRef
333.
Guo W, Sun Y, Liu W, et al. Small molecule-driven mitophagy-mediated NLRP3 inflammasome inhibition is responsible for the prevention of colitis-associated cancer. Autophagy. 2014;10(6):972–85.PubMedPubMedCentralCrossRef
334.
Gong Z, Zhao S, Zhou J, et al. Curcumin alleviates DSS-induced colitis via inhibiting NLRP3 inflammsome activation and IL-1beta production. Mol Immunol. 2018;104:11–9.PubMedCrossRef
335.
Abdullaha M, Mohammed S, Ali M, et al. Discovery of quinazolin-4(3 H)-ones as NLRP3 inflammasome inhibitors: computational design, metal-free synthesis, and in vitro biological evaluation. J Org Chem. 2019;84(9):5129–40.PubMedCrossRef
336.
Abderrazak A, Couchie D, Mahmood DF, et al. Anti-inflammatory and antiatherogenic effects of the NLRP3 inflammasome inhibitor arglabin in ApoE2.Ki mice fed a high-fat diet. Circulation. 2015;131(12):1061–70.PubMedCrossRef
337.
Flores J, Noel A, Foveau B, et al. Caspase-1 inhibition alleviates cognitive impairment and neuropathology in an Alzheimer’s disease mouse model. Nat Commun. 2018;9(1):3916.PubMedPubMedCentralCrossRef
338.
Bauer C, Duewell P, Mayer C, et al. Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasome. Gut. 2010;59(9):1192–9.PubMedCrossRef
339.
Rudolphi K, Gerwin N, Verzijl N, et al. Pralnacasan, an inhibitor of interleukin-1β converting enzyme, reduces joint damage in two murine models of osteoarthritis. Osteoarthr Cartil. 2003;11(10):738–46.CrossRef
340.
Ross J, Brough D, Gibson RM, et al. A selective, non-peptide caspase-1 inhibitor, VRT-018858, markedly reduces brain damage induced by transient ischemia in the rat. Neuropharmacology. 2007;53(5):638–42.PubMedCrossRef
341.
Wang P, Pan B, Tian J, et al. Ac-FLTD-CMK inhibits pyroptosis and exerts neuroprotective effect in a mice model of traumatic brain injury. NeuroReport. 2021;32(3):188–97.PubMedCrossRef
342.
Sun Y, Guo Y. Expression of caspase-1 in breast cancer tissues and its effects on cell proliferation, apoptosis and invasion. Oncol Lett. 2018;15(5):6431–5.PubMedPubMedCentral
343.
Chai D, Qiu D, Zhang Z, et al. Absent in melanoma 2 enhances anti-tumour effects of CAIX promotor controlled conditionally replicative adenovirus in renal cancer. J Cell Mol Med. 2020;24(18):10744–55.PubMedPubMedCentralCrossRef
344.
Chen-Deutsch X, Kutner A, Harrison JS, et al. The pan-caspase inhibitor Q-VD-OPh has anti-leukemia effects and can interact with vitamin D analogs to increase HPK1 signaling in AML cells. Leuk Res. 2012;36(7):884–8.PubMedPubMedCentralCrossRef
345.
Lacy SE, Wu C, Ambrosi DJ, et al. Generation and characterization of ABT-981, a dual variable domain immunoglobulin (DVD-Ig(TM)) molecule that specifically and potently neutralizes both IL-1alpha and IL-1beta. MAbs. 2015;7(3):605–19.PubMedPubMedCentralCrossRef
346.
Chevalier X, Conrozier T, Richette P. Desperately looking for the right target in osteoarthritis: the anti-IL-1 strategy. Arthritis Res Ther. 2011;13(4):124.PubMedPubMedCentralCrossRef
347.
Han C, Yang Y, Guan Q, et al. New mechanism of nerve injury in Alzheimer’s disease: beta-amyloid-induced neuronal pyroptosis. J Cell Mol Med. 2020;24(14):8078–90.PubMedPubMedCentralCrossRef
348.
Metadata
Title
Involvement of inflammasomes in tumor microenvironment and tumor therapies
Authors
Ziqi Zhang
Xue Li
Yang Wang
Yuquan Wei
Xiawei Wei
Publication date
01-12-2023
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2023
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/s13045-023-01407-7

Other articles of this Issue 1/2023

Journal of Hematology & Oncology 1/2023 Go to the issue

Review

Unresolved questions in CLL treatment

Research

Myeloid-like tumor hybrid cells in bone marrow promote progression of prostate cancer bone metastasis

Research

FBXO22 promotes leukemogenesis by targeting BACH1 in MLL-rearranged acute myeloid leukemia

Research

Synergistic efficacy of simultaneous anti-TGF-β/VEGF bispecific antibody and PD-1 blockade in cancer therapy

Review

Metabolism, metabolites, and macrophages in cancer

Review

Advances in single-cell RNA sequencing and its applications in cancer research
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits